BioSpace News Archive

Emergex Vaccines Holding Limited provided an update on its first-in-human clinical trials of its Dengue and Coronavirus T cell Adaptive Vaccine candidates.

Lygos, Inc., a vertically integrated biotechnology provider of sustainable specialty ingredients, and Flexible Solutions International, Inc., a developer and manufacturer of biodegradable products, announced they have entered into a definitive merger agreement providing for an all-stock transaction.

Castle Biosciences, Inc. announced a recent poster presentation highlighting data and concluding that its non-invasive skin scraping technique produces sufficient ribonucleic acid to assess reproducible gene expression for its inflammatory skin disease pipeline test.

Blue Spark Technologies, Inc., a leader in wearable remote patient monitoring solutions, announced that it has raised a $40 million intellectual property-based debt solution to fund growth led by GT Investment Partners with support from Aon plc.

Ocugen, Inc. today announced that they have entered into an amendment to their Co-development, Supply and Commercialization Agreement to expand Ocugen’s exclusive territory to include commercialization of COVAXIN™ in Mexico.

ContraFect Corporation announces today that the Company has been selected for an oral presentation and six poster presentations at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting to be held from April 23-26, 2022 in Lisbon, Portugal.

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the first quarter of 2022 after market close on Monday, May 9, 2022.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the first patient has commenced treatment in its Phase 1 KN-4802 (NCT05242822) clinical trial evaluating its lead Fibroblast Growth Factor Receptor (FGFR) product candidate, KIN-3248.

Takeda (TSE:4502/NYSE:TAK) today announced TAKHZYRO® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.

Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that it has acquired Cell&Co BioServices, headquartered in Clermont-Ferrand, France with additional operations in Pont-du-Château, France.